Xeris Q3 product revenue slightly misses; updates 2025 revenue guidance

Xeris Biopharma Holdings

06/11/2025 12:14

Overview

Xeris Q3 product revenue grows 40% YoY to $74 mln, slightly missing estimates

Recorlev revenue grew 109% YoY to $37 mln, driven by increased patient demand

Company updates 2025 revenue guidance to $285-$290 mln, reflecting 42% growth at midpoint

Outlook

Xeris Biopharma updates 2025 revenue guidance to $285-$290 mln from $280-$290 mln

Company focuses on executing strategy to sustain growth into 2026

Result Drivers

RECORLEV DEMAND - Recorlev revenue grew 109% YoY to $37 mln, driven by increased patient demand

GVOKE INVENTORY - Decrease in COGS due to reduced Gvoke inventory write-offs

REVENUE GUIDANCE UPDATE - Co updates 2025 total revenue guidance to $285-$290 mln, reflecting 42% growth at midpoint

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
Slight Miss*
$74.06 mln
$74.18 mln (5 Analysts)
Q3 EPS
Q3 Net Income
$621,000
Q3 Operating Income
$6.73 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $10.00, about 1.3% above its November 5 closing price of $9.87

The stock recently traded at 76 times the next 12-month earnings vs. a P/E of 188 three months ago

Press Release: ID:nBw401DNba

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)